SkinBioTherapeutics (LON:SBTX) CEO Dr Cath O’Neill worked in the field of gastroenterology, investigating the effect of probiotics on the intestinal barrier function, an area which had already seen significant commercial success through health foods and yoghurt drinks.
But after working with a group of dermatologists in her university lab she wondered whether probiotics could also be used to promote skin health by applying them directly to skin.
“It wasn’t quite a light bulb moment, but it felt natural to ask the question; whether probiotics could be used topically,” said O’Neill.